Ropivacaine: Difference between revisions

Jump to navigation Jump to search
m (Protected "Ropivacaine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 55: Line 55:
[[pt:ropivacaína]]
[[pt:ropivacaína]]


{{SIB}}
 
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 15:46, 20 August 2012

Ropivacaine
File:Ropivacaine.png
Clinical data
Pregnancy
category
Routes of
administration
Parenteral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
Pharmacokinetic data
Bioavailability87%–98% (epidural)
MetabolismHepatic (CYP1A2-mediated)
Elimination half-life1.6–6 hours (varies with administration route)
ExcretionRenal 86%
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H26N2O
Molar mass274.4 g/mol

WikiDoc Resources for Ropivacaine

Articles

Most recent articles on Ropivacaine

Most cited articles on Ropivacaine

Review articles on Ropivacaine

Articles on Ropivacaine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ropivacaine

Images of Ropivacaine

Photos of Ropivacaine

Podcasts & MP3s on Ropivacaine

Videos on Ropivacaine

Evidence Based Medicine

Cochrane Collaboration on Ropivacaine

Bandolier on Ropivacaine

TRIP on Ropivacaine

Clinical Trials

Ongoing Trials on Ropivacaine at Clinical Trials.gov

Trial results on Ropivacaine

Clinical Trials on Ropivacaine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ropivacaine

NICE Guidance on Ropivacaine

NHS PRODIGY Guidance

FDA on Ropivacaine

CDC on Ropivacaine

Books

Books on Ropivacaine

News

Ropivacaine in the news

Be alerted to news on Ropivacaine

News trends on Ropivacaine

Commentary

Blogs on Ropivacaine

Definitions

Definitions of Ropivacaine

Patient Resources / Community

Patient resources on Ropivacaine

Discussion groups on Ropivacaine

Patient Handouts on Ropivacaine

Directions to Hospitals Treating Ropivacaine

Risk calculators and risk factors for Ropivacaine

Healthcare Provider Resources

Symptoms of Ropivacaine

Causes & Risk Factors for Ropivacaine

Diagnostic studies for Ropivacaine

Treatment of Ropivacaine

Continuing Medical Education (CME)

CME Programs on Ropivacaine

International

Ropivacaine en Espanol

Ropivacaine en Francais

Business

Ropivacaine in the Marketplace

Patents on Ropivacaine

Experimental / Informatics

List of terms related to Ropivacaine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ropivacaine (rINN) (Template:PronEng) is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin.

History

Ropivacaine was developed after bupivacaine was noted to be associated with cardiac arrest in 0.5–0.75% of cases, particularly in pregnant women. Ropivacaine was found to have less cardiotoxicity than bupivacaine in animal models.

Clinical use

Indications

Ropivacaine is indicated for local anaesthesia including infiltration, nerve block, epidural and intrathecal anaesthesia in adults and children over 12 years. It is also indicated for peripheral nerve block and caudal epidural in children 1–12 years for surgical pain. It is also sometimes used for infiltration anaesthesia for surgical pain in children.

Ropivacaine is often co-administered with fentanyl for epidural analgesia, for example in pregnant women during labour.

Contraindications

Ropivacaine is contraindicated for IV regional anaesthesia (IVRA).

Adverse effects

Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.

Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.[1]

Treatment of overdose: "Lipid rescue"

As for bupivacaine, there is evidence that Intralipid, a commonly available intravenous lipid emulsion, can be effective in treating severe cardiotoxicity secondary to local anaesthetic overdose in animal experiments[2] and in humans.[3][4][5]

References

  1. Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
  2. Weinberg, G, Ripper, R, Feinstein, DL, Hoffman W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med 2003;28:198-202. PMID 12772136
  3. Picard J, Meek T. Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia 2006;61:107-9. PMID 16430560
  4. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful Use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006;105:217-8. PMID 16810015
  5. Litz, RJ, Popp M, Stehr S N, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia 2006;61:800-1.

de:Ropivacain


Template:WH Template:WS